Breast cancer female

• Role of contrast enhanced mammography with Iomeprol 400 mgI/ml (Iomeron, Bracco), in the identification of breast cancer: I3-MaC Study Not authorised
  2024-513251-32-00 6 "Breast cancer"
• A multicentre, prospective, open-label study with [68Ga]Ga-ABY-025 PET-imaging to characterize HER2-expression and explore the therapy-predi … Pending
  2024-512721-89-00 4 "Breast Cancer"
• NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan+pembrolizumab vs. SoC chemotherapy in clinical st … Pending
  2024-516734-35-00 5 "triple-negative early breast cancer"
• Study of Antibiotic Combinations in Early Breast Cancer Pending
  2024-517993-94-00 4 "Breast Cancer"
• Assessing Oxytocin's Role in Mitigating Psychosocial Stress in Breast Cancer Survivors Pending
  2024-519383-40-00 5 "breast cancer"
• Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/ … Recruiting
  2025-522484-15-00 5 2026-04-27 "ER+/HER2- early breast cancer"
• The POWER trial: A randomised, two-armed open label phase 3 clinical trial on personalised dose optimisation with adjuvant tamoxifen therapy … Recruiting
  2025-522240-40-00 5 2026-03-05 "Breast Cancer"
• A clinical study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside routine endocrine treatment in pa … Recruiting
  2024-511392-15-00 5 2025-11-20 "HR+/HER2- advanced breast cancer"
• zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric ra … Recruiting
  2023-509598-22-01 6 2025-05-13 "Oncology - Breast cancer"
• First -in-Human Study of DS-3939a in Subjects with Advanced Solid Tumors Recruiting
  2023-507937-14-00 7 2025-03-25 "Metastatic Solid Tumor"
• NeoAdjuvant study comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab treatment in low-risk, triple-negative early br … Recruiting
  2023-508787-29-00 4 2024-10-10 "Triple-negative early breast cancer with low risk for recurr"
• CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE … Recruiting
  2022-500764-35-00 6 2022-10-13 "Patients with advanced HER2-negative, hormone receptor posit"
• NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+ … Recruitment ended
  2024-514458-61-01 4 2024-02-05 "HER2+ early breast cancer"
• Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Recruitment ended
  2023-510390-33-00 5 2020-10-23 "HER2-negative breast cancer patients with high relapse risk "
• A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi … Recruitment ended
  2023-509242-35-00 5 2020-07-23 "HR+/HER2- early breast cancer"
• Phase III Study of Capivasertib + Fulvestrant vs Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2 … Recruitment ended
  2023-505042-25-00 5 2020-05-05 "Locally advanced (inoperable) or metastatic HR+/HER2 breast "
• Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk … Recruitment ended
  2024-515769-32-00 5 2019-07-02 "HR+/HER2- early breast cancer"
• Chemotherapy or chemotherapy + hormonotherapy in women over 70 with HER2 receptor-negative but estrogen receptor-positive breast cancer acco … Recruitment ended
  2024-516996-34-00 5 2012-04-12 "oestrogen-receptor (ER)-positive HER2-negative breast carcin"
• Pilot study to explore the diagnostic value of gadopiclenol in pathological and radiological insights with multiparametric MRI enhancement i … Ended
  2025-521810-24-00 6 2025-09-22 "Breast cancer"
• COMPRENDO - A PHASE II OPEN LABEL STUDY FOR THE COMPREHENSIVE ANALYSIS OF PREDICTORS OF THE TREATMENT WITH PEMBROLIZUMAB AND OLAPARIB IN PAT … Ended
  2024-519350-37-00 4 "patients with unresectable or metastatic HER2 negative breas"

Showing 1–20 of 20 trials